Tissue pharmacokinetics of clonidine in rats

Altered norepinephrine transmission after spatial learning impairs sleep-mediated memory consolidation in rats

The therapeutic use of noradrenergic drugs makes the evaluation of their effects on cognition of high priority. Norepinephrine (NE) is an important neuromodulator for a variety of cognitive processes and may importantly contribute to sleep-mediated memory consolidation. The NE transmission fluctuates with the behavioral and/or brain state and influences associated neural activity. Here, we assessed the effects of altered NE transmission after learning of a hippocampal-dependent task on neural activity and spatial memory in adult male rats. We administered clonidine (0.05 mg/kg, i.p.; n = 12 rats) or propranolol (10 mg/kg, i.p.; n = 11) after each of seven daily learning sessions on an 8-arm radial maze. Compared to the saline group (n = 9), the drug-treated rats showed lower learning rates. To assess the effects of drugs on cortical and hippocampal activity, we recorded prefrontal EEG and local field potentials from the CA1 subfield of the dorsal hippocampus for 2 h after each learning session or drug administration. Both drugs significantly reduced the number of hippocampal ripples for at least 2 h. An EEG-based sleep scoring revealed that clonidine made the sleep onset faster while prolonging quiet wakefulness. Propranolol increased active wakefulness at the expense of non-rapid eye movement (NREM) sleep. Clonidine reduced the occurrence of slow oscillations (SO) and sleep spindles during NREM sleep and altered the temporal coupling between SO and sleep spindles. Thus, pharmacological alteration of NE transmission produced a suboptimal brain state for memory consolidation. Our results suggest that the post-learning NE contributes to the efficiency of hippocampal-cortical communication underlying memory consolidation.

Mechanism of stress-induced attacks in an episodic neurologic disorder

Stress is the most common trigger among episodic neurologic disorders. In episodic ataxia type 2 (EA2), physical or emotional stress causes episodes of severe motor dysfunction that manifest as ataxia and dystonia. We used the tottering (tg/tg) mouse, a faithful animal model of EA2, to dissect the mechanisms underlying stress-induced motor attacks. We find that in response to acute stress, activation of α1-adrenergic receptors (α1-Rs) on Purkinje cells by norepinephrine leads to their erratic firing and consequently motor attacks. We show that norepinephrine induces erratic firing of Purkinje cells by disrupting their spontaneous intrinsic pacemaking via a casein kinase 2 (CK2)-dependent signaling pathway, which likely reduces the activity of calcium-dependent potassium channels. Moreover, we report that disruption of this signaling cascade at a number of nodes prevents stress-induced attacks in the tottering mouse. Together, our results suggest that norepinephrine and CK2 are required for the initiation of stress-induced attacks in EA2 and provide previously unidentified targets for therapeutic intervention.

Preclinical evaluation of reconsolidation blockade by clonidine as a potential novel treatment for posttraumatic stress disorder

Exposure to traumatic events can lead to posttraumatic stress disorder (PTSD). Current PTSD treatments typically only produce partial improvement. Hence, there is a need for preclinical research to identify new candidate drugs and to develop novel therapeutic approaches. Animal studies have indicated that fear memories can be weakened by blocking restabilization after retrieval, a process known as reconsolidation. Furthermore, evidence suggests that there are important alterations of the noradrenergic system in PTSD, and hence it may be of interest to study drugs that target this pathway. Here, we investigated the efficacy of clonidine, an α₂-adrenoreceptor agonist, to block reconsolidation in an animal model of persistent traumatic memories. Using an auditory fear conditioning paradigm in rats, we tested the efficacy of clonidine to weaken fear memory retention when administered systemically after retrieval. We evaluated dosage, number of treatments, and specificity in reconsolidation blockade. We found that postretrieval administration of clonidine disrupts fear-related memories in a dose-dependent manner and that two treatments are sufficient for maximal memory impairment. Furthermore, we determined that this effect is long lasting and specific to reconsolidation processes as shown by the selectivity to affect reactivated memories and the absence of spontaneous recovery and of postreactivation short-term memory impairment. Our results demonstrate the efficacy of systemic administration of clonidine following retrieval to persistently disrupt fear memory retention through reconsolidation blockade. This study provides important preclinical parameters for future therapeutic strategies involving clonidine to block reconsolidation as a novel treatment for PTSD symptoms.

N-(Imidazolidin-2-ylidene)-1-arylmethanamine oxides: synthesis, structure and pharmacological evaluation

A high yielding three-step procedure was applied for the synthesis of N-(imidazolidin-2-ylidene)-1-arylmethanamine oxides 3 (α-aminonitrones) starting from the easily accessible imidazolidin-2-one O-benzyl oxime 1. The α-aminonitrone-α-iminohydroxyloamine tautomerism of these products was studied theoretically and the structures of the synthesised compounds were confirmed by single crystal X-ray crystallographic analysis. The compounds were evaluated in vitro for their binding affinities to α(1) and α(2) adrenoceptors as well as imidazoline I(1) and I(2) receptors. The highest potencies at the α(2) adrenergic receptors were observed for compounds bearing biphenyl (4h, K(i)  = 9 nM) and naphthyl (4i, K(i)  = 92 nM) moieties. Compounds 4h and 4i were further tested in vivo for their cardiovascular and sedative-hypnotic effects in rats.

Evidence of a pharmacodynamic EEG profile in rats following clonidine administration using a nonlinear analysis

BACKGROUND

Changes caused by clonidine in rodent electroencephalograms (EEG) have been reported with some inconsistency. For this reason, a pre-clinical study was conducted in order to confirm previous findings with both a standard spectral analysis and a sleep stage scoring procedure. In addition, a nonlinear technique for analysing the time-varying signals was implemented to compare its performance against conventional approaches.

RESULTS

The nonlinear method succeeds in quantifying all dose-related responses from the data set relying solely on the EEG trace.

CONCLUSIONS

Nonlinear approaches can deliver a suitable alternative to the sleep-stage scoring methods commonly used for drug effect detection.

Comparative plasma and tissue pharmacokinetics and drug residue profiles of different chemotherapeutants in fowls and rabbits

Blood and tissue pharmacokinetics and drug residue profiles of six chemotherapeutants were studied. Ceftriaxone (CEF), intravenously at 50 mg/kg, sulfamonomethoxine (SMM) and sulfaquinoxaline (SQ), orally at 200 mg/kg, and olaquindox (OLA), orally at 50 mg/kg, were administered to young broilers. Penicillin (PEN), intramuscularly at 200,000 U/kg, and albendazole (ALB), orally at 20 mg/kg, were given to rabbits. For each drug, 13-18 groups (n = 5-10 individuals/group) of the dosed animals were killed at different post-dosing times. Drug and/or metabolite concentrations in plasma, liver, kidney, heart, lung, and muscle tissues were analysed by HPLC procedures. Multi-exponential kinetic models were fitted to the observed tissue concentration-time data by applying a non-linear least-squares regression computer program. Tissue half-life, peak tissue concentration, and time of peak tissue concentration were determined. Half-life of CEF, SMM, SQ, OLA, PEN, ALB, and two metabolites of ALB (sulfoxide and sulfone) in various tissues ranged 0.6-1.4, 4.7-9.0, 4.5-18.9, 1.8-3.1, 0.9-3.0, 3.4-9.6, 5.0-16.1 and 7.4-12.2 h. The times required for CEF, SMM, SQ, OLA, PEN, and ALB residue concentrations to decline to 0.1 microgram/g in various tissues ranged from 5.0-11.6, 70.0-110.5, 114.0-179.8, 21.3-30.3, 4.1-24.8 and 47.8-84.4 h. Drug kinetic characteristics in tissues differed significantly from those in plasma, and also varied from tissue to tissue. It is necessary, therefore, to evaluate tissue kinetics when designing dosage regimens in tissue infection chemotherapy with these drugs. Knowledge of tissue kinetics is also important in predicting and controlling drug residues in edible tissues of food-producing animals.

Serum glucose and insulin levels in normotensive (WKY) and spontaneously hypertensive (SH) rats during and after the cessation of continuous (10 day) clonidine infusion

The concentrations of glucose were elevated whereas those of insulin were decreased in the sera of normotensive Wistar-Kyoto (WKY) and spontaneously hypertensive (SH) rats on day 10 of a continuous subcutaneous infusion of clonidine (10 micrograms kg-1 h-1 for 10 days). Fifteen to 18 h after cessation of infusion, the glucose levels of both strains had fallen to below those of the respective controls whereas the insulin levels remained suppressed. As such the hypoglycaemia may be related to the general increase in metabolic requirements associated with the post-infusion 'withdrawal syndrome'.

Pharmacokinetics and antihypertensive effects of low dose clonidine during chronic therapy

Using a sensitive and specific radioimmunoassay the pharmacokinetic disposition of clonidine was determined in hypertensive patients after a single dose and then after 5, 28 and 56 days of chronic dosing with 75 micrograms bd. Following a single dose of clonidine maximal plasma concentrations of 0.34 +/- 0.06 ng/ml were achieved after 3.6 +/- 1.2 hours. After 5 days of repetitive dosing the maximal concentration was significantly higher, 0.66 +/- 0.06 ng/ml and remained so throughout chronic therapy (P = 0.018). The AUC, Tmax and T1/2 did not differ significantly between the acute dose and the chronic dosing pharmacokinetic studies. Clonidine also produced a significant fall in blood pressure. Supine diastolic blood pressure fell from 106 +/- 5 mmHg predose to 99 +/- 6 mmHg 2 hours after the first dose (P less than 0.05). The corresponding values after cyclopenthiazide alone were 108 +/- 8 and 105 +/- 8 mmHg (P = 0.13). Similar falls in blood pressure were produced during chronic therapy.

Modification of the circadian body temperature rhythm of the spontaneously hypertensive rat during and following cessation of continuous clonidine infusion

The effects of continuous clonidine infusion (10 micrograms/kg/h for 10 days) and the cessation of this infusion on the circadian body temperature rhythm of the spontaneously hypertensive (SH) rat were examined. This circadian rhythm was blunted significantly during the infusion of clonidine. The fall in body temperature which normally occurs at the onset of each light phase was attenuated during the clonidine infusion, and as such, these rats displayed a relative hyperthermia over the light but not the dark phases. On cessation of infusion (24:00 h), a distinct hyperthermia occurred within the immediate dark phase and the subsequent light phase. The results demonstrate that the circadian control of body temperature is disturbed both during and after continuous clonidine infusion.

Modification of clonidine-induced pressor responses in morphine-dependent and hypophysectomised rats

Pressor responses to successive doubling doses of clonidine were examined in anaesthetised normotensive (NT) and spontaneously hypertensive rats (SHR). The slope of the dose-response curves was similar in both strains of rat, but the average response to the same concentrations of clonidine was less in the SHR. Naloxone (2 mg/kg i.v.) did not alter the dose-response curve in either strain. However, in NT and SHR made morphine-dependent (3 X 75 mg morphine pellets s.c.) and in hypophysectomised rats the increase in blood pressure was significantly reduced compared to the untreated or sham operated control groups, with a decrease in both the slope of the dose-response curve and a decrease in the average response. These results suggest that opioid peptide systems can modify vascular reactivity although not via circulating peptides. The specificity of the effects remains to be established.

Body temperature during and following 10-day subcutaneous infusion of clonidine in the rat

Body temperature in the rat was measured during and after cessation of the continuous subcutaneous infusion of clonidine (10 micrograms/kg per hr) for 10 days. The body temperature of control animals displayed a distinct circadian rhythm. On each day the mean body temperature over the dark phase (2000-0800 hr) was consistently higher (0.6-0.9 degrees C) than the following light phase. The infusion of clonidine was essentially devoid of initial effects on body temperature. However, during the light phases of day 2 onwards the mean body temperature of the animals treated with clonidine was consistently higher (0.4-0.6 degrees C) than that of controls. No such differences were observed during the dark phases. It appeared that the infusion of clonidine limited the fall in body temperature which normally occurred at the onset of the light phases and this resulted in the treated rats displaying a relative hyperthermia. On cessation of the infusion of clonidine (at 2400 hr on day 11) a distinct hyperthermia was observed within 2 hr and was sustained for the remainder of the dark phase and subsequent light phase. This post-infusion hyperthermia was more pronounced than that observed during the period of infusion of clonidine. These results demonstrate that the circadian control of body temperature is disturbed both during and after continuous infusion of clonidine.

The involvement of central alpha adrenoceptors in the antihypertensive actions of methyldopa and clonidine in the rat

The antihypertensive effects of methyldopa and clonidine result from agonist activity at alpha adrenoceptor sites within the brain. Methyldopa is converted enzymatically to alpha-methylnoradrenaline in noradrenergic neurones in rat brain and replaces the natural transmitter, noradrenaline. Radioligand receptor studies show that alpha-methylnoradrenaline differs from noradrenaline in being much more selective (70 times) for the alpha 2 subclass of adrenoceptors than noradrenaline and it is likely that the antihypertensive action of methyldopa results from selective activation of alpha 2 adrenoceptors by alpha-methylnoradrenaline in the nucleus tractus solitarius and the anterior hypothalamus. Radioligand studies also show that clonidine is a selective alpha 2 adrenoceptor agonist although it probably interacts with alpha 1 adrenoceptors at higher concentrations. With regard to a withdrawal syndrome after cessation of clonidine treatment, the cardiovascular and behavioural components can now be characterised in a rat model. The components include increases in basal blood pressure and heart rate, as well as increases in cardiovascular reactivity and also increases in rapid eye movement (REM) sleep, body shakes and tremor which is reminiscent of an opiate withdrawal syndrome. Increased central noradrenergic activity is involved in this syndrome and alpha 1 and alpha 2 adrenoceptors mediate opposing effects on the REM sleep rebound component.